In response to requests for proposals from researchers in these four critical areas, LLS is awarding these grants under its Translational Research Program, an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.
The RFPs mark LLS's aggressive and proactive approach to addressing the challenge of improving outcomes forwith particularly urgent needs. LLS aims to stimulate more academic research in these areas: the malignant in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS); non-cutaneous T-cell malignancies; high-risk myeloma; and long-term and late effects of blood cancer therapies. The grants recipients are:
in AML and MDS and the identification of potential targeted therapies:
- Alan D'Andrea, M.D., Targeting ID1 in Acute Myeloid Leukemia
- James Griffin, M.D., Aberrant splicing in AML: novel molecular markers and therapeutic targets
- H. Leighton Grimes, Ph.D., Children's Hospital Medical Center of Cincinnati, RNA Therapeutics for Leukemia
- Monica Guzman, Ph.D., Joan & Sanford I. Weill Medical College of Strategies to eliminate leukemia during remission
- Duane Hassane, Ph.D., Joan & Sanford I. Weill Medical College of Cornell University, Significance and Mechanisms of Genomic Diversity in AML
- Anthony Letai, M.D., Ph.D., Personalizing AML therapy by BH3 profiling AML
- Ross Levine, M.D., Targeting cytosine hydroxymethylation in AML
- A. Thomas Look, M.D., Targeting of nuclear export in primary AML cells
- Li Zhang, MSc, M.D., Ph.D, Preventing AML relapse by targeting with double-negative T-cells
Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders:
- Jaroslaw Maciejewski, M.D., Ph.D., Cleveland Clinic Foundation, Implications of STAT3 Mutations in Large Granular Lymphocyte Leukemia
- Owen O'Connor, M.D., Ph.D., Epigenetic Approaches to PTCL Therapy
Development of therapeutic strategies for the high risk myeloma patient:
- Jennifer Carew, Ph.D., at Targeting SIRT1 in
- Irene Ghobrial, M.D., Targeting Hypoxic and Metabolic pathways in
- Christoph Heuck, M.D., for Medical Sciences, Targeting DNA methylation in the diagnosis and therapy of high-risk myeloma
- Alexander Stewart, M.D., Development of Novel Therapeutics Targeting High Risk Myeloma
Mechanisms underlying long term and late effects resulting from
and the development of measures to significantly reduce or prevent these toxicities
- Smita Bhatia, M.D., M.P.H., City of Hope, Bone Marrow Transplant Survivor Study-2
- Eric Chow, M.P.H., Dexrazoxane and prevention of anthracycline-related cardiomyopathy
- Ruben Niesvizky, M.D., Joan & Sanford I. Weill Medical College of Cornell University, alterations in lenalidomide treated myeloma patients
- Pavan Reddy, M.D., Alpha 1-antitypsin as a novel strategy to modulate GVHD
- Daniela Salvemini, Ph.D, Blocking bortezomib induced painful peripheral neuropathy with FTY720
LLS also announced the awarding of an additional 28 TRP grants, totaling $15.6 million, to scientists working in other areas of blood cancer research.
"By issuing RFP's LLS is taking a strategic approach to identifying and prioritizing areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particularly difficult diseases," said Richard Winneker, Ph.D., LLS's SVP, Research.
About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered inNY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.
Contact: Andrea Greif (914) 821-8958 [email protected]
SOURCE The Leukemia & Lymphoma Society